CN104587098A - Medicament for treating fatty liver - Google Patents
Medicament for treating fatty liver Download PDFInfo
- Publication number
- CN104587098A CN104587098A CN201510058596.5A CN201510058596A CN104587098A CN 104587098 A CN104587098 A CN 104587098A CN 201510058596 A CN201510058596 A CN 201510058596A CN 104587098 A CN104587098 A CN 104587098A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- herba
- fatty liver
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a medicament for treating fatty liver. The medicament is characterized by comprising the following components in parts by weight: 4-10 parts of herba epimedii, 3-6 parts of folium eriobotryae, 1-3 parts of radix glycyrrhizae, 2-5 parts of radix scutellariae, 2-7 parts of rhizoma alismatis, 3-10 parts of radix notoginseng, 2-6 parts of poria, 1-5 parts of fructus crataegi, 2-4 parts of herba artemisiae scopariae, 3-10 parts of fructus lycii, 3-8 parts of herba abri, 3-6 parts of gynostemma pentaphyllum, 1-5 parts of herba rhodiolae, 2-8 parts of radix salviae miltiorrhizae and 3-8 parts of green tea. The medicament has the efficacies of soothing the liver and regulating qi, resolving stasis eliminating phlegm and promoting blood circulation and removing stasis, the curative effect for treating fatty liver is definite, the effect is fast and good, and the medicament is safe and free from toxic and side effect.
Description
Technical field
The invention belongs to technical field of Chinese medicines, be specifically related to a kind of medicine for the treatment of fatty liver.
Background technology
Along with the change of people's living and diet structure and the raising of medical imaging technology, fatty liver disease (i.e. fatty liver) sickness rate being called as modern times " affluenza " significantly improves, become the second largest frequently-occurring hepatopathy being only second to viral hepatitis, human health in serious threat.Probably there is Patients with Fatty Liver more than 8,000 ten thousand people in current China, just has one to be potential Patients with Fatty Liver in every 10 people.Fatty liver disease can be caused by multiple inducement, and pathological changes main body, at lobules of liver, is one of common DHD, store up too much with triglyceride in hepatocyte (TG) and diffusivity hepatic cell fattydegeneration for major pathologic features.
Generally speaking, fatty liver belongs to reversibility disease, and early diagnosis also treatment in time can recover normal, but as treated not in time, can further develop and become hepatitis, liver cirrhosis, hepatocarcinoma etc.The drug main being used for the treatment of fatty liver at present clinically will be divided into hypolipidemic, liver-protecting fat-dropping medicine and Chinese medicine three major types, hypolipidemic comprises fibrate, trihydroxy methyl glutaryl-CoA-reductase inhibitors etc., because fatty liver is often with Liver Lipid Metabolism obstacle, blood lipid-lowering medicine orders about blood fat and more concentrates on liver and carry out metabolism, and then infringement liver function.
Summary of the invention
The technical problem to be solved in the present invention is to provide a kind of medicine for the treatment of fatty liver.
Technical scheme provided by the invention is a kind of medicine for the treatment of fatty liver, comprises the component of following weight portion: Herba Epimedii 4 ~ 10 parts, Folium Eriobotryae 3 ~ 6 parts, 1 ~ 3 part, Radix Glycyrrhizae, Radix Scutellariae 2 ~ 5 parts, Rhizoma Alismatis 2 ~ 7 parts, Radix Notoginseng 3 ~ 10 parts, 2 ~ 6 parts, Poria, Fructus Crataegi 1 ~ 5 part, Herba Artemisiae Scopariae 2 ~ 4 parts, Fructus Lycii 3 ~ 10 parts, Herba Abri 3 ~ 8 parts, Herb Gynostemmae Pentaphylli 3 ~ 6 parts, Radix Rhodiolae 1 ~ 5 part, Radix Salviae Miltiorrhizae 2 ~ 8 parts, green tea 3 ~ 8 parts.
Said medicine also comprises Fructus Lycopersici esculenti herb 3 ~ 10 parts, leaf of Herba Rosmarini Officinalis 1 ~ 5 part, 1 ~ 5 part, Folium olive.
The preparation method of said medicine is as follows: each raw material is added mixing and is placed in container, add the soak by water 3 times of inventory weight 10 ~ 20 times, each decoction 1 ~ 3h, merge decoction liquor, filter, it is the extractum of 1.20 ~ 1.30 that filtrate is concentrated into relative density at 60 DEG C, adds adjuvant, makes corresponding dosage form.
Medicine of the present invention has effect of depressed liver-energy dispersing and QI regulating, kidney and spleen invigorating, blood stasis dispersing and phlegm expelling dampness removing, blood circulation promoting and blood stasis dispelling, treatment fatty liver determined curative effect, rapid-action, effective, safe without toxic side effect.
Detailed description of the invention
The present invention is further elaborated for following specific embodiment, but not as a limitation of the invention.
Embodiment 1
Formula: Herba Epimedii 4kg, Folium Eriobotryae 3kg, Radix Glycyrrhizae 1kg, Radix Scutellariae 2kg, Rhizoma Alismatis 2kg, Radix Notoginseng 3kg, Poria 2kg, Fructus Crataegi 1kg, Herba Artemisiae Scopariae 2kg, Fructus Lycii 3kg, Herba Abri 3kg, Herb Gynostemmae Pentaphylli 3kg, Radix Rhodiolae 1kg, Radix Salviae Miltiorrhizae 2kg, green tea 3kg.
Preparation method: above-mentioned each raw material is placed in container, adds the soak by water 3 times of inventory weight 10 times, decocts 1h at every turn, merges decoction liquor, and filter, it is the extractum of 1.20 that filtrate is concentrated into relative density at 60 DEG C, adds adjuvant, makes tablet, every sheet 0.2g.
Embodiment 2
Formula: Herba Epimedii 10kg, Folium Eriobotryae 6kg, Radix Glycyrrhizae 3kg, Radix Scutellariae 5kg, Rhizoma Alismatis 7kg, Radix Notoginseng 10kg, Poria 6kg, Fructus Crataegi 5kg, Herba Artemisiae Scopariae 4kg, Fructus Lycii 10kg, Herba Abri 8kg, Herb Gynostemmae Pentaphylli 6kg, Radix Rhodiolae 5kg, Radix Salviae Miltiorrhizae 8kg, green tea 8kg.
Preparation method: above-mentioned each raw material is placed in container, adds the soak by water 3 times of inventory weight 20 times, decocts 3h at every turn, merges decoction liquor, and filter, it is the extractum of 1.30 that filtrate is concentrated into relative density at 60 DEG C, adds adjuvant, makes tablet, every sheet 0.2g.
Embodiment 3
Formula: Herba Epimedii 8kg, Folium Eriobotryae 5kg, Radix Glycyrrhizae 2kg, Radix Scutellariae 3kg, Rhizoma Alismatis 4kg, Radix Notoginseng 6kg, Poria 4kg, Fructus Crataegi 3kg, Herba Artemisiae Scopariae 3kg, Fructus Lycii 5kg, Herba Abri 5kg, Herb Gynostemmae Pentaphylli 4kg, Radix Rhodiolae 3kg, Radix Salviae Miltiorrhizae 6kg, green tea 5kg, Fructus Lycopersici esculenti herb 10kg, leaf of Herba Rosmarini Officinalis 5kg, Folium olive 5kg.
Preparation method: above-mentioned each raw material is placed in container, adds the soak by water 3 times of inventory weight 15 times, decocts 2h at every turn, merges decoction liquor, and filter, it is the extractum of 1.25 that filtrate is concentrated into relative density at 60 DEG C, adds adjuvant, makes pill, every 0.2g.
Embodiment 4
Formula: Herba Epimedii 4kg, Folium Eriobotryae 6kg, Radix Glycyrrhizae 1kg, Radix Scutellariae 5kg, Rhizoma Alismatis 2kg, Radix Notoginseng 10kg, Poria 2kg, Fructus Crataegi 5kg, Herba Artemisiae Scopariae 2kg, Fructus Lycii 10kg, Herba Abri 3kg, Herb Gynostemmae Pentaphylli 6kg, Radix Rhodiolae 1kg, Radix Salviae Miltiorrhizae 8kg, green tea 3kg, Fructus Lycopersici esculenti herb 10kg, leaf of Herba Rosmarini Officinalis 1kg, Folium olive 5kg.
Preparation method: above-mentioned each raw material is placed in container, adds the soak by water 3 times of inventory weight 10 times, decocts 3h at every turn, merges decoction liquor, and filter, it is the extractum of 1.20 that filtrate is concentrated into relative density at 60 DEG C, adds adjuvant, makes pill, every 0.2g.
For verifying effect of the present invention, applicant spy carries out following experiment.
1, physical data
Choose clinical case 400 example, male 226 example, women 174 example, 22 ~ 62 years old age, alcohol fatty hepatopath 189 example, nonalcoholic fatty liver disease 211 example.Be divided into 4 groups at random, often organize 100 examples, be respectively experimental group 1 ~ 4.
2, diagnostic criteria
" new Chinese medicine guideline of clinical investigations " that the People's Republic of China's traditional Chinese medicine industry standard " disease of tcm Standardization of diagnosis and curative effect " issued with reference to State Administration of Traditional Chinese Medicine and Ministry of Public Health are issued, diagnostic criteria is as follows:
Primary symptom: 1) weak; 2) hypochondriac pain; 3) abdominal distention.
Secondary disease: 1) the lower mass in the abdomen of the side of body; 2) indigestion and loss of appetite; 3) obesity; 4) light red tongue has indentation, white and thin fur, in vain greasy or BOHUANG and greasy; 5) stringy and rolling pulse or moisten.
All possess primary symptom, and secondary disease 1 can be defined as primary disease.
Tcm symptom quantization modulation standard:
3, Therapeutic Method
Experimental group 1 ~ 4 takes the medicine of embodiment 1 ~ 4 respectively, every day 1 time, and each 3 slices/for oral administration, within one week, be a course for the treatment of, the course for the treatment of is 4 weeks.
4, the standard of curative effect evaluation
Integration × 100% before TCM syndrome therapeutic index=(before treatment the rear integration of integration-treatment)/treatment
Effective: after terminating the course for the treatment of, TCM syndrome therapeutic index >=70%;
Effective: after treatment terminates, TCM syndrome therapeutic index >=30%;
Invalid: after treatment terminates, TCM syndrome therapeutic index < 30%.
5, therapeutic outcome
Group | Effective | Effectively | Invalid | Total effective rate (%) |
Experimental group 1 | 42 | 48 | 10 | 90 |
Experimental group 2 | 46 | 45 | 9 | 91 |
Experimental group 3 | 52 | 41 | 7 | 93 |
Experimental group 4 | 48 | 43 | 9 | 91 |
Claims (3)
1. treat a medicine for fatty liver, it is characterized in that: the component comprising following weight portion: Herba Epimedii 4 ~ 10 parts, Folium Eriobotryae 3 ~ 6 parts, 1 ~ 3 part, Radix Glycyrrhizae, Radix Scutellariae 2 ~ 5 parts, Rhizoma Alismatis 2 ~ 7 parts, Radix Notoginseng 3 ~ 10 parts, 2 ~ 6 parts, Poria, Fructus Crataegi 1 ~ 5 part, Herba Artemisiae Scopariae 2 ~ 4 parts, Fructus Lycii 3 ~ 10 parts, Herba Abri 3 ~ 8 parts, Herb Gynostemmae Pentaphylli 3 ~ 6 parts, Radix Rhodiolae 1 ~ 5 part, Radix Salviae Miltiorrhizae 2 ~ 8 parts, green tea 3 ~ 8 parts.
2. the medicine for the treatment of fatty liver according to claim 1, is characterized in that: also comprise Fructus Lycopersici esculenti herb 3 ~ 10 parts, leaf of Herba Rosmarini Officinalis 1 ~ 5 part, 1 ~ 5 part, Folium olive.
3. the medicine for the treatment of fatty liver according to claim 1, it is characterized in that: its preparation method is as follows: each raw material is added mixing and is placed in container, add the soak by water 3 times of inventory weight 10 ~ 20 times, each decoction 1 ~ 3h, merge decoction liquor, filter, it is the extractum of 1.20 ~ 1.30 that filtrate is concentrated into relative density at 60 DEG C, add adjuvant, make corresponding dosage form.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510058596.5A CN104587098A (en) | 2015-02-04 | 2015-02-04 | Medicament for treating fatty liver |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510058596.5A CN104587098A (en) | 2015-02-04 | 2015-02-04 | Medicament for treating fatty liver |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104587098A true CN104587098A (en) | 2015-05-06 |
Family
ID=53113369
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510058596.5A Pending CN104587098A (en) | 2015-02-04 | 2015-02-04 | Medicament for treating fatty liver |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104587098A (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102727686A (en) * | 2012-07-20 | 2012-10-17 | 杨献华 | Traditional Chinese medicine composition for treating fatty liver |
CN102988629A (en) * | 2011-09-08 | 2013-03-27 | 彭军 | Medicine used for treating fatty liver |
-
2015
- 2015-02-04 CN CN201510058596.5A patent/CN104587098A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102988629A (en) * | 2011-09-08 | 2013-03-27 | 彭军 | Medicine used for treating fatty liver |
CN102727686A (en) * | 2012-07-20 | 2012-10-17 | 杨献华 | Traditional Chinese medicine composition for treating fatty liver |
Non-Patent Citations (2)
Title |
---|
尹常健,等。: ""脂肪肝常用治法述要"", 《山东中医杂志》 * |
王永怡,等。: "《脂肪肝防治与饮食调养必读》", 31 May 2009 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102755594A (en) | Traditional Chinese medicine composition for treating acute and chronic hepatitis B and preparation method thereof | |
CN104644915A (en) | Pharmaceutical composition for treating alcoholic liver diseases as well as preparation method and application of pharmaceutical composition | |
CN103933468A (en) | Traditional Chinese medicine for treating acute pancreatitis | |
CN103330865B (en) | Medicine for curing non-alcoholic steatohepatitis and preparation method thereof | |
CN103099944A (en) | Drug for treating stubborn insomnia | |
CN102641430B (en) | Traditional Chinese medicine decoction for treating diabetic nephropathy (DN) | |
CN102727787B (en) | Drug with characteristics of rapid transaminase lowering and live protection | |
CN104043050A (en) | Traditional Chinese medicine composition for treating cholecystitis | |
CN109954034A (en) | A kind of preparation method for treating chill, wind-heat, the drug of influenza and its oral solution | |
CN103845429A (en) | Traditional Chinese medicine for treating chronic hepatitis | |
CN102579971A (en) | Chinese medicine preparation for curing hyperplasia of mammary glands | |
CN101926903A (en) | Chinese medicine preparation for curing facial paralysis | |
CN103100035B (en) | Traditional Chinese medicine (TCM) decoction for treating globus hysteriocus | |
CN104721256A (en) | Anwei Yang extract as well as preparation method and medical application thereof | |
CN105267818B (en) | A kind of Chinese medicine composition and preparation method thereof for treating epigastric pain | |
CN103860882A (en) | Medicinal preparation for treating chronic cervicitis | |
CN104587098A (en) | Medicament for treating fatty liver | |
CN103007204B (en) | Chinese medicinal composition for treating hepatofibrosis | |
CN102106992B (en) | Chinese medicinal granules for treating non-alcoholic steatohepatitis | |
CN104800675A (en) | Medicament for treating active ulcerative colitis | |
CN104288579A (en) | Traditional Chinese medicine for treating chronic nephritis and preparation method thereof | |
CN104127602A (en) | Traditional Chinese medicine for treating fatty liver | |
CN102335243B (en) | Chinese medicinal composition for treating icteric hepatitis | |
CN103212033B (en) | Drug composition for treating viral hepatitis | |
CN102166303B (en) | Chinese medicinal composition for treating chronic atrophic gastritis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150506 |
|
RJ01 | Rejection of invention patent application after publication |